{
    "2018-06-26": [
        [
            {
                "time": "2018-03-01",
                "original_text": "How Pfizerâ€™s Valuation Compares",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "valuation",
                        "compares"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-02",
                "original_text": "Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies",
                "features": {
                    "keywords": [
                        "Lilly",
                        "diabetes",
                        "drugs",
                        "phase III",
                        "endpoints"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-03",
                "original_text": "Merck's Keytruda Under FDA Review for Advanced Melanoma",
                "features": {
                    "keywords": [
                        "Merck",
                        "Keytruda",
                        "FDA",
                        "review",
                        "advanced melanoma"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-04",
                "original_text": "Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies",
                "features": {
                    "keywords": [
                        "Lilly",
                        "diabetes",
                        "drugs",
                        "phase III",
                        "endpoints"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-05",
                "original_text": "Is Pfizer's Lead Growth Driver in Trouble?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "growth driver",
                        "trouble"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-06",
                "original_text": "Is Pfizer's Lead Growth Driver in Trouble?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "growth driver",
                        "trouble"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-07",
                "original_text": "See what the IHS Markit Score report has to say about Eli Lilly And Co.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "Eli Lilly",
                        "report"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}